uniQure N.V. filings document regulatory, financial, governance, and capital-structure disclosures for a Nasdaq-listed gene therapy company incorporated in the Netherlands. Form 8-K reports cover operating results, corporate updates, Regulation FD disclosures, and clinical or regulatory communications involving programs such as AMT-130 for Huntington’s disease.
Proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and related pay-versus-performance disclosures. The filing record also includes formal disclosure categories for material agreements, financing arrangements, risk-related updates, and capital-structure matters connected to uniQure’s development-stage gene therapy portfolio.
Jack Kaye filed a Form 144 reporting a proposed sale of 7,970 ordinary shares attributable to restricted stock units vesting on 06/11/2026. The filing lists Citigroup Global Markets, Inc. as the broker. It also records a prior sale of 2,645 shares on 06/03/2026.
UniQure N.V. reported a sale of 2,645 ordinary shares on 06/10/2026 via a stock options exercise and sale pursuant to a 10b5-1 plan. The filing also lists vested share items of 3,127 shares (vested 02/27/2020) and 1,780 shares (vested 02/25/2021), described as compensation-related. The excerpt identifies the broker as Citigroup Global Markets, Inc. and indicates transactions on NASDAQ.
uniQure N.V. director Kaye Jack reported an option exercise paired with a share sale. On June 3, 2026, Jack exercised stock options to acquire 2,645 Ordinary Shares at $16.04 per share and sold 2,645 Ordinary Shares in open-market transactions at an average price of $30.01 per share. These transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025. After the trades, Jack directly owned 20,439 Ordinary Shares, and the exercised stock option for 2,645 shares, which had vested in full on February 24, 2023, was fully used.
uniQure N.V. filed an Amendment No. 4 to a Schedule 13G/A reporting shared beneficial ownership of 2,586,356 Ordinary Shares. The filing states this represents 4.1% of the class based on 62,529,408 Shares outstanding as of February 26, 2026. The reporting persons are RTW Investments, LP and Roderick Wong, M.D., reporting shared voting and dispositive power over the same 2,586,356 shares. The statement notes the RTW Funds have the right to receive dividends or proceeds from these Shares.
uniQure N.V. Chief Medical Officer Walid Abi-Saab reported an exercise-and-sell transaction in Ordinary Shares. On May 8, 2026, he sold a total of 45,000 Ordinary Shares in open-market transactions at weighted-average prices around $25.00–$25.29, executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 26, 2025.
On the same date, he exercised 25,000 stock options with a $5.59 exercise price, receiving an equal number of Ordinary Shares. After these transactions, he directly held 169,669 Ordinary Shares and 60,500 stock options expiring on March 1, 2034, indicating he retains a substantial equity stake.
State Street Corporation reports shared beneficial ownership of 2,260,512 shares of Uniqure N.V. common stock, representing 3.6% of the class as reported on 03/31/2026. The filing lists shared voting power of 2,230,049 and identifies affiliated investment adviser entities.
The filing is a Schedule 13G disclosure showing passive/beneficial ownership by institutional holders and names SSGA Funds Management, State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company and State Street Global Advisors, Ltd. as related entities.
Uniqure N.V. submitted a Form 144 notice reporting proposed sales of Ordinary Shares to be effected through Citigroup Global Markets, Inc. on 05/08/2026. The filing lists 45,000 (figure present) and details 20,000 vested shares and 25,000 shares from option exercises.
FMR LLC filed an amendment to Schedule 13G reporting beneficial ownership of 1,743,807.87 shares of UNIQURE N.V. common stock, representing 2.8% of the class. The filing lists sole dispositive power for 1,743,807.87 shares and sole voting power of 1,741,237 shares. The cover names Abigail P. Johnson in connection with FMR LLC and references an exhibit for a 13d-1(k)(1) agreement.